

Operational Summary

for the Fiscal Year Ended March 31, 2021

May 12, 2021

Mitsubishi Chemical Holdings Corporation

Table of Contents


Consolidated Financial Statements for FY2020		Page No.	References 1		Page No.
Statements of Operations	5		Number of Subsidiaries and Affiliates and Overseas Sales Revenue and Core Operating Income	23	
Sales Revenue and Core Operating Income by Business Segment	6		Statements of Operations [Quarterly Data]	24	
Analysis of Core Operating Income	7		Sales Revenue and Core Operating Income by Business Segment [Quarterly Data]	25	
Overview of Business Segments	8		Core Operating Income (Loss) by Business Segment [New Business Segment basis]	26	
Special Items	12		Special Items [Quarterly Data]	27	
Cash Flows	13		Capital Expenditure, Depreciation & Amortization, R&D Expenses, and Number of Employees by Business Segment	28	
Statements of Financial Positions	14		Trend of Performance	29	
FY2021 Forecasts	Page No.		Trend of Financial Position	30	
Business Segments : Changes from Fiscal 2020	16		References 2	Page No.	
Business Segment Information	18		Consolidated financial results for the Fiscal Year Ended March 31, 2021 (MTPC)	32	
Statement of Operations	19				
Sales Revenue and Core Operating Income	20				
Dividend Forecast	21				

List of Abbreviations

FY2021	April 1, 2021 – March 31, 2022	
	1st Half (1H):	April 1, 2021 – September 30, 2021
	2nd Half (2H):	October 1, 2021 – March 31, 2022
FY2020	April 1, 2020 – March 31, 2021	
	1st Quarter (1Q):	April 1, 2020 – June 30, 2020
	2nd Quarter (2Q):	July 1, 2020 – September 30, 2020
	3rd Quarter (3Q):	October 1, 2020 – December 31, 2020
	4th Quarter (4Q):	January 1, 2021 – March 31, 2021
	1st Half (1H):	April 1, 2020 – September 30, 2020
	2nd Half (2H):	October 1, 2020 – March 31, 2021
FY2019	April 1, 2019 – March 31, 2020	
MCHC	Mitsubishi Chemical Holdings Corporation	
MCC	Mitsubishi Chemical Corporation	
MTPC	Mitsubishi Tanabe Pharma Corporation	
LSII	Life Science Institute, Inc.	
NSHD	Nippon Sanso Holdings Corporation	

Core Operating Income (Loss) by Business Segment [Quarterly Data]

(Billions of Yen)



Consolidated Statements of Operations

Exchange Rate (¥/\$)	106.3	105.6	105.9	109.0	(3.1)	(3%)
Naphtha Price (¥/kl)	27,600	35,000	31,300	42,900	(11,600)	(27%)

(Billions of Yen)

				FY2019	Difference	%	
	1H	2H	FY2020				
Continuing Operations * 2	Sales Revenue	1,504.8	1,752.7	3,257.5	3,580.5	(323.0)	(9%)
	Core Operating Income *1	54.6	120.1	174.7	194.8	(20.1)	(10%)
	Special Items	(82.7)	(44.5)	(127.2)	(50.5)	(76.7)	
	Operating Income (Loss)	(28.1)	75.6	47.5	144.3	(96.8)	(67%)
	Financial Income/Expenses (Dividend included above)	(8.7) [2.8]	(5.9) [1.5]	(14.6) [4.3]	(22.3) [4.2]	7.7 [0.1]	
	(Foreign Exchange Gain/Loss included above)	[(0.4)]	[2.8]	[2.4]	[(3.7)]	[6.1]	
	Income (Loss) before Taxes	(36.8)	69.7	32.9	122.0	(89.1)	
	Income Taxes	(3.1)	(7.1)	(10.2)	(52.3)	42.1	
	Net Income (Loss) from Continuing Operations	(39.9)	62.6	22.7	69.7	(47.0)	
	Net Income from Discontinued Operations *3	-	-	-	16.9	(16.9)	
Net Income (Loss)	(39.9)	62.6	22.7	86.6	(63.9)		
Net Income (Loss) Attributable to Owners of the Parent	(49.7)	42.1	(7.6)	54.1	(61.7)	-	
Net Income (Loss) Attributable to Non-Controlling Interests	9.8	20.5	30.3	32.5	(2.2)		
	1.1	11.8	12.9	13.4	(0.5)		

*1 Share of profit of associates and joint ventures included.

*2 Discontinued operations are not included.

*3 Figures for FY2019, include ¥15.8 billion from gain on share exchanges after tax.

Core operating income is calculated as operating income (loss) excluding certain gains and expenses attributable to non-recurring factors (losses incurred by business withdrawal and streamlining, etc.).

Sales Revenue and Core Operating Income (Loss) by Business Segment

(Billions of Yen)

		1H	2H	FY2020	FY2019	Difference
Total Consolidated	Sales Revenue	1,504.8	1,752.7	3,257.5	3,580.5	(323.0)
	Core Operating Income	54.6	120.1	174.7	194.8	(20.1)
Functional Products	Sales Revenue	293.1	331.5	624.6	680.4	(55.8)
	Core Operating Income	17.4	17.8	35.2	39.5	(4.3)
Performance Chemicals	Sales Revenue	180.5	228.8	409.3	437.7	(28.4)
	Core Operating Income	4.1	22.0	26.1	21.8	4.3
Performance Products	Sales Revenue	473.6	560.3	1,033.9	1,118.1	(84.2)
	Core Operating Income	21.5	39.8	61.3	61.3	0.0
MMA	Sales Revenue	114.6	136.0	250.6	262.5	(11.9)
	Core Operating Income	1.8	13.0	14.8	23.8	(9.0)
Petrochemicals	Sales Revenue	182.6	247.6	430.2	534.4	(104.2)
	Core Operating Income	(12.5)	11.0	(1.5)	(2.1)	0.6
Carbon Products	Sales Revenue	83.8	93.6	177.4	246.6	(69.2)
	Core Operating Income	(3.9)	4.8	0.9	8.1	(7.2)
Chemicals	Sales Revenue	381.0	477.2	858.2	1,043.5	(185.3)
	Core Operating Income	(14.6)	28.8	14.2	29.8	(15.6)
Industrial Gases	Sales Revenue	381.4	430.4	811.8	843.3	(31.5)
	Core Operating Income	35.6	49.5	85.1	88.0	(2.9)
Health Care	Sales Revenue	194.0	196.6	390.6	393.1	(2.5)
	Core Operating Income	13.4	4.5	17.9	16.5	1.4
Others	Sales Revenue	74.8	88.2	163.0	182.5	(19.5)
	Core Operating Income	(1.3)	(2.5)	(3.8)	(0.8)	(3.0)
[Inventory valuation gain/loss]						
	Performance Chemicals	(0.8)	2.9	2.1	(1.1)	3.2
	Petrochemicals	(14.8)	6.6	(8.2)	(0.1)	(8.1)
	Carbon Products	(1.4)	0.0	(1.4)	(1.6)	0.2
	Total	(17.0)	9.5	(7.5)	(2.8)	(4.7)

*1 Breakdown figures of segment are approximation for reference purpose only.

*2 From Q2 FY2020, Qualicaps, Inc. has been reclassified from the Health Care segment to the Performance Products segment (Performance Chemicals).

In addition, the segmentation of certain businesses and consolidated subsidiaries in MCC has been reclassified. The segment information for FY2019 is accordingly restated.


Analysis of Core Operating Income (Loss)

(Billions of Yen)

	FY2020	FY2019	Difference				
				Price	Volume	Fixed Cost	Others *
Total Consolidated	174.7	194.8	(20.1)	(5.0)	(39.3)	18.2	6.0
Performance Products	61.3	61.3	0.0	4.8	(22.1)	6.8	10.5
Chemicals	14.2	29.8	(15.6)	(2.6)	(7.3)	3.4	(9.1)
Industrial Gases	85.1	88.0	(2.9)	4.7	(7.5)	0.4	(0.5)
Health Care	17.9	16.5	1.4	(12.5)	(2.3)	7.6	8.6
Others	(3.8)	(0.8)	(3.0)	0.6	(0.1)	0.0	(3.5)

* Items included are impacts from inventory valuation gain/loss and share of profit of associates and joint ventures, etc.

Changes in exchange rates	(0.9)	(2.1)	(0.4)	-	1.6
Changes in foreign currency translation included in above		(0.2)			




Performance Products Segment

(Billions of Yen)

		FY2020	FY2019	Difference
Functional Products	Sales Revenue	624.6	680.4	(55.8)
	Core Operating Income	35.2	39.5	(4.3)
Performance Chemicals	Sales Revenue	409.3	437.7	(28.4)
	Core Operating Income	26.1	21.8	4.3
Performance Products	Sales Revenue	1,033.9	1,118.1	(84.2)
	Core Operating Income	61.3	61.3	0.0

Functional Products	
Sales Revenue	Despite demand picking up from the second half, sales volumes of high-performance engineering plastics and other offerings for automotive applications were down from the previous year.
Core Operating Income	Earnings dropped amid lower sales volumes for high-performance engineering plastics and other offerings.
Performance Chemicals	
Sales Revenue	Sales volumes were down for performance polymers for automotive applications and other offerings, while sales volumes also dropped for phenol-polycarbonate chain materials because of scheduled maintenance and repairs and other factors.
Core Operating Income	Despite lower sales volumes by impact of scheduled maintenance and repairs, earnings increased due to price of phenol-polycarbonate chain materials improving and other factors.

< Analysis of Core Operating Income >



<Major initiatives>

- In April 2020, MCC decided to acquire Gelest, Inc., and made it a consolidated subsidiary in October. This purchase will enable MCC to broaden its customer solutions by combining its advanced technologies, business resources, and customer network with Gelest's capabilities. Gelest's key strengths include its advanced molecular design and compounding technologies in silicon compounds for contact lens materials, antimicrobials, and other materials, and the extensive use of the company's metal compounds for semiconductor precursors and other materials.
- In October 2020, MCC and Ube Industries, Ltd., established joint venture MU Ionic Solutions Corporation based on a joint incorporation-type split plan agreed in July 2020. The new entity has succeeded the electrolyte businesses of both partners, as announced in March 2020.


Chemicals Segment

(Billions of Yen)

		FY2020	FY2019	Difference
MMA	Sales Revenue	250.6	262.5	(11.9)
	Core Operating Income	14.8	23.8	(9.0)
Petrochemicals	Sales Revenue	430.2	534.4	(104.2)
	Core Operating Income	(1.5)	(2.1)	0.6
Carbon Products	Sales Revenue	177.4	246.6	(69.2)
	Core Operating Income	0.9	8.1	(7.2)
Chemicals	Sales Revenue	858.2	1,043.5	(185.3)
	Core Operating Income	14.2	29.8	(15.6)

MMA	
Sales Revenue	Revenue declined despite improving prices in the second half in the MMA monomer and other markets, as market prices were lower than a year earlier.
Core Operating Income	Earnings dwindled owing mainly to smaller gap between raw materials and product prices amid weaker market conditions.
Petrochemicals	
Sales Revenue	Revenue dropped reflecting lower sales volume due to greater impact from scheduled maintenance and repairs at the ethylene production facility, and also owing to a decline in selling prices in tandem with a drop in raw materials costs.
Core Operating Income	Core operating income was flat year-on-year. Despite the greater impact from scheduled maintenance and repairs and inventory valuation losses arisen from lower raw materials prices, the price gap between raw material costs and product selling prices widened.
Carbon Products	
Sales Revenue	Revenue was down amid lower prices as a result of reduced raw materials costs and a drop in sales volumes from declining in demand for coke and other offerings.
Core Operating Income	Earnings were down, as sales volumes dwindled amid lower demand.

<Analysis of Core Operating Income>



<Major initiatives>

- MCC decided to implement metallurgical coke business reforms at its Kagawa Plant to optimize production and sales systems. These efforts will include reducing the number of coke ovens from 323, to 250, and doubling export shipping facilities to two lines, the second becoming operational from the end of March 2022.
- MCC decided to end MMA monomer and MAA production (with an annual capacity of 135,000 metric tons) at the Beaumont site, its consolidated subsidiary in Texas, the United States, and closed that facility at the end of March 2021.


- MCC acquired a green field property in Geismar, Louisiana, the United States to construct a 350,000 metric ton MMA plant that would leverage its proven, proprietary new ethylene method (Alpha technology). The company looks to finalize its investment decision by the middle of 2022, making the plant operational by the end of 2025.

Industrial Gases Segment

		(Billions of Yen)		
		FY2020	FY2019	Difference
Industrial Gases	Sales Revenue	811.8	843.3	(31.5)
	Core Operating Income	85.1	88.0	(2.9)

Industrial Gases	
Sales Revenue	Although demand for electronics-related gases remained strong, revenue was down amid lower domestic and overseas demand.
Core Operating Income	Earnings declined amid lower overall domestic and overseas demand.

< Analysis of Core Operating Income >



<Major initiatives>

- TNSC adopted a holding company structure and changed its tradename to Nippon Sanso Holdings Corporation on October 1, 2020. The company seeks to establish a competitive group operation framework as a global gas major.


Health Care Segment

(Billions of Yen)

		FY2020	FY2019	Difference
Health Care	Sales Revenue	390.6	393.1	(2.5)
	Core Operating Income	17.9	16.5	1.4

Health Care	
Sales Revenue	Revenue was flat year-on-year primarily attributable to a growth in higher sales volumes mainly for priority products, and despite impact from National Health Insurance drug price revisions in domestic ethical pharmaceuticals business.
Core Operating Income	Earnings were increased owing to a decrease in sales costs and research and development expenditures mainly reflecting constrained activities in tandem with the spread of COVID-19.

< Analysis of Core Operating Income >



Note:

Royalty revenue from Novartis Pharma AG for *Gilenya*, a treatment agent for multiple sclerosis, was reduced, because a part of the royalty revenue was not recognized as sales revenue in accordance with IFRS 15 due to the start of arbitration proceedings.

<Major initiatives>

- In July 2020, MTPC received approval for edaravone (branded *Radicava* in the United States) as an intravenous treatment for amyotrophic lateral sclerosis in Indonesia, followed by Japan, South Korea, the United States, Canada, Switzerland, and China.
- In March 2021, Medicago Inc. (Canada), embarked on the Phase 3 portion of Phase 2/3 clinical trials for its plant-derived virus-like particle (VLP) vaccine candidate (project code: MT-2766) for the prevention of COVID-19.
- In March 2021, MTPC acquired manufacturing and marketing approval in Japan for *UPLIZNA* for I.V. Infusion 100mg, which is a treatment for prevention of relapses of neuromyelitis optica spectrum disorder (including neuromyelitis optica).

- In January 2021, LSII commenced clinical trials for the Muse cell-based product CL2020 for the treatment of amyotrophic lateral sclerosis (ALS) as well as acute myocardial infarction, ischemic stroke, epidermolysis bullosa and spinal cord injury.

Consolidated Special Items

(Billions of Yen)

	4Q	FY2020	FY2019	Difference
Total Special Items	(14.3)	(127.2)	(50.5)	(76.7)
Impairment loss	(11.1)	(118.3)	(43.9)	(74.4)
Loss on restructuring of subsidiaries and affiliates	(7.4)	(7.4)	-	(7.4)
Loss on sale and disposal of fixed assets	(1.8)	(6.2)	(9.9)	3.7
Special retirement expenses	(0.1)	(5.5)	(2.0)	(3.5)
Provision for loss on plant closure	-	(3.3)	-	(3.3)
Cancellation penalty	-	(1.9)	-	(1.9)
Gain on sale of property, plant and equipment	0.0	8.6	7.9	0.7
Gain on arbitration award	4.1	4.1	-	4.1
Share of profit of associates and joint ventures	0.1	2.8	-	2.8
Gain on business transfer	1.4	1.4	-	1.4
Gain on step acquisitions	-	1.3	-	1.3
Gain on sales of shares of subsidiaries and associates	0.3	1.2	0.5	0.7
Others	0.2	(4.0)	(3.1)	(0.9)

*Loss on Beaumont site closure ¥23.6 billion (impairment loss ¥19.4 billion, special retirement expenses ¥0.9 billion, provision for loss ¥3.3 billion)

[Special Items by Business Segment]

Performance Products	(11.3)	(15.3)	(1.9)	(13.4)
Chemicals	(1.0)	(27.0)	(2.4)	(24.6)
Industrial Gases	(1.0)	1.7	2.1	(0.4)
Health Care	(0.1)	(79.6)	(41.5)	(38.1)
Others	(0.9)	(7.0)	(6.8)	(0.2)

Consolidated Cash Flows

	Based on statements of cash flows		Adjusted cash flows *1	
	FY2020	FY2019	FY2020	FY2019
Net cash provided by (used in) operating activities	467.1	452.0	467.1	452.0
Income before taxes	32.9	147.6	32.9	147.6
Depreciation and amortization	243.8	239.8	243.8	239.8
Change in operating receivables/payables	(27.5)	42.7	(27.5)	42.7
Change in Inventories	44.6	7.1	44.6	7.1
Others	173.3	14.8	173.3	14.8
Net cash provided by (used in) investment activities	(217.0)	(87.6)	(287.0)	(205.7)
Capital expenditure	(257.0)	(236.1)	(257.0)	(236.1)
Sale of assets	30.8	30.3	30.8	30.3
Investment and loans receivable, etc.	9.2	118.2	(60.8)	0.1
Free cash flow	250.1	364.4	180.1	246.3
Net cash provided by (used in) financing activities	(142.8)	(450.5)		
Interest bearing debts	(4.4)	37.3		
Additional acquisition of consolidated subsidiaries' stocks *2	(98.8)	(399.8)		
Dividends, etc.	(39.6)	(88.0)		
Net increase (decrease) in cash and cash equivalents	107.3	(86.1)		
Effect of exchange rate changes and changes in scope of consolidation	14.1	(7.2)		
Cash and cash equivalents at the beginning of the period	228.2	321.5		
Cash and cash equivalents at the end of the period	349.6	228.2		

(Billions of Yen)

*1 Adjusted cash flows based on actual results are calculated by excluding cash flows from investment of surplus funds for explanatory purposes.

*2 Additional acquisitions of MTPC shares(¥95.4 billion in Fiscal 2021, ¥398.1 billion in Fiscal 2020)

Consolidated Statements of Financial Positions

	(Billions of Yen)		
	Mar.31.2021	Mar.31.2020	Difference
Cash & cash equivalents	349.6	228.2	121.4
Trade receivables	716.4	698.5	17.9
Inventories	576.5	606.5	(30.0)
Others	155.0	216.1	(61.1)
Current assets	1,797.5	1,749.3	48.2
Fixed assets	2,269.2	2,252.8	16.4
Goodwill	671.9	616.8	55.1
Investments & Other	548.6	513.2	35.4
Non-current assets	3,489.7	3,382.8	106.9
Total assets	5,287.2	5,132.1	155.1

	(Billions of Yen)		
	Mar.31.2021	Mar.31.2020	Difference
Interest-bearing debt	2,482.4	2,388.1	94.3
Trade payables	382.3	398.1	(15.8)
Others	851.4	895.1	(43.7)
Liabilities	3,716.1	3,681.3	34.8
Share capitals, Retained earnings, etc.,	1,226.5	1,234.5	(8.0)
Other components of equity	9.8	(64.3)	74.1
Equity attributable to owners of the parent	1,236.3	1,170.2	66.1
Non-controlling interests	334.8	280.6	54.2
Equity	1,571.1	1,450.8	120.3
Total liabilities & equity	5,287.2	5,132.1	155.1

Net Interest-bearing debt *1	2,132.8	2,089.9	42.9
Net D/E ratio	1.73	1.79	(0.06)
Ratio of Equity attributable to owners of the parent	23.4%	22.8%	0.6%
ROE *2	(0.6%)	4.2%	(4.8%)

*1 Net interest-bearing debt (End of Mar.31, 2021)

= interest-bearing debt (2,482.4 billion yen)

- {cash and cash equivalents (349.6 billion yen) + investments of surplus funds (0.0 billion yen)}

Note : Interest-bearing debt includes lease obligations.


*2 Ratio of net income attributable to owners of the parent.

Consolidated Financial Results Forecasts for FY2021

Business Segments : Changes from Fiscal 2020

<FY2020>

Business Domain	Business Segment	Business Sub-Segment
Performance Products	Performance Products	Functional Products
		Performance Chemicals
Industrial Materials	Chemicals	MMA
		Petrochemicals
		Carbon Products
	Industrial Gases	
Health Care	Health Care	
Others	Others	



Change the breakdown of Performance Products

<FY2021>

Business Domain	Business Segment	Business Sub-Segment
Performance Products	Performance Products	Polymers & Compounds
		Films & Molding Materials
		Advanced Solutions
Industrial Materials	Chemicals	MMA
		Petrochemicals
		Carbon Products
	Industrial Gases	
Health Care	Health Care	
Others	Others	

* Changes other than the breakdown of Performance Products

- Engineering Polymers(other than Polycarbonate) :
Performance Chemicals → Petrochemicals
- Acrylonitrile : MMA → Petrochemicals
- Utility : Petrochemicals → Others

New and old correspondence table of the reporting segments (fiscal year ended March 2021 basis)

<Before>				<After>					
(Billions of Yen)				(Billions of Yen)					
Business Segment	Business Sub-Segment	Sales Revenue	Core Operating Income	Business Segment	Business Sub-Segment	Sales Revenue	Core Operating Income		
	Functional Products	624.6	35.2	① Polymers & Compounds		271.8	15.0		
	Performance Chemicals	409.3	26.1		② Films & Molding Materials		413.8	27.6	
Performance Products		1,033.9	61.3			③ Advanced Solutions		308.9	17.1
	MMA	250.6	14.8						994.5
	Petrochemicals	430.2	(1.5)	⑤ Petrochemicals		231.1	13.1		
	Carbon Products	177.4	0.9		⑥ Carbon Products		479.8	1.7	
Chemicals		858.2	14.2				177.4	1.0	
Industrial Gases		811.8	85.1	Chemicals		888.3	15.8		
Health Care		390.6	17.9	Industrial Gases		811.8	85.1		
Others		163.0	(3.8)	Health Care		390.6	17.9		
Total Consolidated		3,257.5	174.7	Others		172.3	(3.8)		
				Total Consolidated		3,257.5	174.7		

- ① Polymers, Coating Material, Additives & Fine
- ② Films, Carbon Fiber, Advanced Materials, Alumina & Fiber
- ③ Aqua & Infrastructure, Semiconductor, Electronics
- ④ Life Solutions, Battery Materials
- ⑤ Engineering Polymers (other than Polycarbonate)
- ⑥ Acrylonitrile
- ⑦ Utility

Business Segment Information

Business Domain	Business Segment	Business Sub-Segment		
			Businesses	
Performance Products	Performance Products	Polymers & Compounds	Polymers	Performance Polymers, Sustainable Polymers Acetyl Polymers
			Coating & Additives	Coating Material, Additives & Fine
		Films & Molding Materials	Films	Packaging, Industrial Films, Polyester Film
			Molding Materials	Carbon Fiber, Advanced Materials, Alumina & Fiber
		Advanced Solutions	Amenity Life	Aqua & Infrastructure, Life Solutions
			Information & Electronics	Semiconductor, Electronics, Battery Materials
Industrial Materials	Chemicals	MMA	MMA	MMA
		Petrochemicals	Petrochemicals	Basic petrochemicals, Polyolefins, Basic chemical derivatives
		Carbon Products	Carbon	Carbon Products
	Industrial Gases		Industrial gases	
Health Care	Health Care			Pharmaceuticals
				Life science

Consolidated Statements of Operations

Exchange Rate (¥/\$)	108.0	108.0	108.0	105.9	2.1
Naphtha Price (¥/kl)	48,000	48,000	48,000	31,300	16,700

(Billions of Yen)

	1H	2H	FY2021 Forecast	FY2020 Actual	Difference	%
Sales Revenue	1,774.0	1,886.0	3,660.0	3,257.5	402.5	12%
Core Operating Income	102.5	127.5	230.0	174.7	55.3	32%
Special Items	(2.0)	(12.0)	(14.0)	(127.2)	113.2	
Operating Income	100.5	115.5	216.0	47.5	168.5	355%
Financial Income/Expenses	(7.0)	(9.0)	(16.0)	(14.6)	(1.4)	
Income before Taxes	93.5	106.5	200.0	32.9	167.1	
Income Taxes	(33.0)	(27.0)	(60.0)	(10.2)	(49.8)	
Net Income	60.5	79.5	140.0	22.7	117.3	
Net Income Attributable to Owners of the Parent	44.0	53.0	97.0	(7.6)	104.6	-
Net Income Attributable to Non-Controlling Interests	16.5	26.5	43.0	30.3	12.7	

Consolidated Sales Revenue and Core Operating Income by Business Segment

(Billions of Yen)

		1H	2H	FY2021 Forecast	FY2020 Actual	Difference
Total Consolidated	Sales Revenue	1,774.0	1,886.0	3,660.0	3,257.5	402.5
	Core Operating Income	102.5	127.5	230.0	174.7	55.3
Polymers & Compounds	Sales Revenue	139.0	143.0	282.0	271.8	10.2
	Core Operating Income	7.5	8.5	16.0	15.0	1.0
Films & Molding Materials	Sales Revenue	216.0	221.0	437.0	413.8	23.2
	Core Operating Income	18.0	17.0	35.0	27.6	7.4
Advanced Solutions	Sales Revenue	169.0	180.0	349.0	308.9	40.1
	Core Operating Income	7.0	11.0	18.0	17.1	0.9
Performance Products	Sales Revenue	524.0	544.0	1,068.0	994.5	73.5
	Core Operating Income	32.5	36.5	69.0	59.7	9.3
MMA	Sales Revenue	135.0	129.0	264.0	231.1	32.9
	Core Operating Income	17.0	15.0	32.0	13.1	18.9
Petrochemicals	Sales Revenue	313.0	330.0	643.0	479.8	163.2
	Core Operating Income	2.0	5.0	7.0	1.7	5.3
Carbon products	Sales Revenue	100.0	95.0	195.0	177.4	17.6
	Core Operating Income	5.0	4.0	9.0	1.0	8.0
Chemicals	Sales Revenue	548.0	554.0	1,102.0	888.3	213.7
	Core Operating Income	24.0	24.0	48.0	15.8	32.2
Industrial Gases	Sales Revenue	415.0	444.0	859.0	811.8	47.2
	Core Operating Income	45.0	49.0	94.0	85.1	8.9
Health Care	Sales Revenue	195.0	228.0	423.0	390.6	32.4
	Core Operating Income	3.0	19.0	22.0	17.9	4.1
Others	Sales Revenue	92.0	116.0	208.0	172.3	35.7
	Core Operating Income	(2.0)	(1.0)	(3.0)	(3.8)	0.8

* Breakdown figures of segment are approximation for reference purpose only.

Dividend Forecast

MCHC's basic policy of returning profits to shareholders emphasizes enhancement of shareholder value by increasing the value of the company. Therefore, using 30% of the medium-term level as a guideline for the consolidated dividend payout ratio, MCHC will make stable dividend payments, while maintaining sufficient internal reserves as resources to develop future businesses.

The expected fiscal year-end dividend per share for FY2020 is 12 yen, which is in line with the forecast released on May 13, 2020. This is scheduled to be approved at the Board of Directors meeting, scheduled for May 19, 2021. Taking into the aforementioned dividend policy, the interim and fiscal year-end dividend forecast for FY2021 is 12 yen, which is equivalent to the fiscal year-end dividend for FY2020.

Accordingly, the expected full-fiscal year dividend for FY2021 is 24 yen.

		FY2021 Forecast	FY2020 Forecast	FY2019 Actual	FY2018 Actual	FY2017 Actual
Cash dividends per share (Yen)	Interim	12	12	20	20	15
	Year-end	12	12	12	20	17
	Annual total	24	24	32	40	32
Net income per share (Yen)	Year-end	¥68.29	(¥5.32)	¥38.08	¥119.22	¥147.14
Consolidated dividend pay out ratio	Annual total	35.1%	—	84.0%	33.6%	21.7%

References 1

Number of Subsidiaries and Affiliates and Overseas Sales Revenue and Core Operating Income

(Number of companies)

Number of subsidiaries and affiliates	FY2020	FY2019	FY2018	FY2017	FY2016
Subsidiaries and affiliated companies	666	698	754	708	731
Companies in consolidation scope	630	659	705	653	592
Consolidated subsidiaries	487	510	550	515	510
Japan	161	174	193	203	193
Overseas	326	336	357	312	317
Joint operation	4	4	4	4	4
Affiliates accounted for by the equity method	137	145	151	134	78
Companies for which the equity method does not apply as they are categorized as assets held for sale	2	-	-	-	-

Sales revenue and core operating income by geographic area based on location of consolidated subsidiaries

(Billions of Yen)

Japan	2,109.5	2,367.8	2,595.6	2,589.6	2,408.6
Overseas	1,148.0	1,212.7	1,244.7	1,134.8	967.5
Sales Revenue	3,257.5	3,580.5	3,840.3	3,724.4	3,376.1
Japan	92.5	99.5	162.3	223.2	211.5
Overseas	82.2	95.3	151.8	157.3	96.0
Core Operating Income	174.7	194.8	314.1	380.5	307.5

Overseas sales revenue based on location of customers

Overseas Sales Revenue	1,464.9	1,534.4	1,664.6	1,547.0	1,333.6
	45.0%	42.9%	43.3%	41.6%	39.5%

Statements of Operations [Quarterly Data]

Exchange Rate (¥/\$)	109.7	107.7	109.3	109.1	107.4	105.3	104.0	107.2
Naphtha Price (¥/kl)	45,400	40,200	41,300	44,800	25,000	30,200	31,300	38,800

(Billions of Yen)

	FY2019				FY2020			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
	Continuing Operations * 2							
Sales Revenue	916.4	911.3	903.1	849.7	722.7	782.1	850.6	902.1
Core Operating Income *1	70.1	60.7	50.2	13.8	15.0	39.6	59.0	61.1
Special Items	(0.2)	0.0	(20.2)	(30.1)	8.7	(91.4)	(30.2)	(14.3)
Operating Income (Loss)	69.9	60.7	30.0	(16.3)	23.7	(51.8)	28.8	46.8
Financial Income/Expenses	(3.3)	(4.9)	(7.7)	(6.4)	(3.3)	(5.4)	(4.8)	(1.1)
(Dividend included above)	[2.9]	[0.1]	[1.1]	[0.1]	[2.5]	[0.3]	[0.7]	[0.8]
(Foreign Exchange Gain/Loss included above)	[(0.3)]	[0.7]	[(2.8)]	[(1.3)]	[0.0]	[(0.4)]	[(0.3)]	[3.1]
Income (Loss) before Taxes	66.6	55.8	22.3	(22.7)	20.4	(57.2)	24.0	45.7
Income Taxes	(18.2)	(19.4)	(15.7)	1.0	(12.2)	9.1	(12.5)	5.4
Net Income (Loss) from Continuing Operations	48.4	36.4	6.6	(21.7)	8.2	(48.1)	11.5	51.1
Net Income from Discontinued Operations	0.5	16.4	-	-	-	-	-	-
Net Income (Loss)	48.9	52.8	6.6	(21.7)	8.2	(48.1)	11.5	51.1
Net Income (Loss) Attributable to Owners of the Parent	37.8	43.5	(5.0)	(22.2)	5.2	(54.9)	1.9	40.2
Net Income (Loss) Attributable to Non-Controlling Interests	11.1	9.3	11.6	0.5	3.0	6.8	9.6	10.9

5.0 3.1 2.6 2.7

0.2 0.9 4.2 7.6

*1 Share of profit of associates and joint ventures included.

*2 Discontinued operations not included.

Sales Revenue and Core Operating Income by Business Segment [Quarterly Data]

(Billions of Yen)

		FY2019				FY2020			
		1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Total Consolidated	Sales Revenue	916.4	911.3	903.1	849.7	722.7	782.1	850.6	902.1
	Core Operating Income	70.1	60.7	50.2	13.8	15.0	39.6	59.0	61.1
Functional Products	Sales Revenue	171.8	175.4	172.3	160.9	142.7	150.4	162.8	168.7
	Core Operating Income	12.6	13.9	9.0	4.0	8.7	8.7	10.1	7.7
Performance Chemicals	Sales Revenue	110.2	109.5	108.6	109.4	87.5	93.0	109.0	119.8
	Core Operating Income	7.1	6.5	4.4	3.8	1.2	2.9	8.3	13.7
Performance Products	Sales Revenue	282.0	284.9	280.9	270.3	230.2	243.4	271.8	288.5
	Core Operating Income	19.7	20.4	13.4	7.8	9.9	11.6	18.4	21.4
MMA	Sales Revenue	77.7	72.1	59.2	53.5	52.5	62.1	64.4	71.6
	Core Operating Income	13.8	11.4	0.5	(1.9)	(1.2)	3.0	4.8	8.2
Petrochemicals	Sales Revenue	134.7	137.1	137.3	125.3	84.2	98.4	115.6	132.0
	Core Operating Income	0.8	1.0	1.0	(4.9)	(13.6)	1.1	2.6	8.4
Carbon Products	Sales Revenue	71.7	63.8	62.2	48.9	44.4	39.4	46.4	47.2
	Core Operating Income	6.0	2.9	1.0	(1.8)	(1.3)	(2.6)	1.3	3.5
Chemicals	Sales Revenue	284.1	273.0	258.7	227.7	181.1	199.9	226.4	250.8
	Core Operating Income	20.6	15.3	2.5	(8.6)	(16.1)	1.5	8.7	20.1
Industrial Gases	Sales Revenue	208.6	210.9	208.8	215.0	182.9	198.5	206.1	224.3
	Core Operating Income	21.1	23.2	22.2	21.5	13.5	22.1	23.3	26.2
Health Care	Sales Revenue	102.5	93.0	112.3	85.3	95.2	98.8	105.7	90.9
	Core Operating Income	9.1	1.2	11.7	(5.5)	8.9	4.5	9.0	(4.5)
Others	Sales Revenue	39.2	49.5	42.4	51.4	33.3	41.5	40.6	47.6
	Core Operating Income	(0.4)	0.6	0.4	(1.4)	(1.2)	(0.1)	(0.4)	(2.1)

*1 Breakdown figures of segment are approximation for reference purpose only.

*2 From Q2 FY2020, Qualicaps, Inc. has been reclassified from the Health Care segment to the Performance Products segment (Performance Chemicals). In addition, the segmentation of certain businesses and consolidated subsidiaries in MCC has been reclassified. The segment information for FY2019 is accordingly restated.

Core Operating Income (Loss) by Business Segment

[New Business Segment basis]

(Billions of Yen)

	FY2017	FY2018	FY2019	FY2020	FY2021 Forecast
Total Consolidated	375.8	314.1	194.8	174.7	230.0
Polymers & Compounds	31.9	23.3	16.4	15.0	16.0
Films & Molding Materials	44.0	26.5	28.0	27.6	35.0
Advanced Solutions	17.3	20.0	18.1	17.1	18.0
Performance Products	93.2	69.8	62.5	59.7	69.0
MMA	103.9	88.5	19.2	13.1	32.0
Petrochemicals	32.8	17.2	1.2	1.7	7.0
Carbon Products	12.5	24.6	8.1	1.0	9.0
Chemicals	149.2	130.3	28.5	15.8	48.0
Industrial Gases	57.5	63.3	88.0	85.1	94.0
Health Care	75.3	53.0	16.5	17.9	22.0
Others	0.6	(2.3)	(0.7)	(3.8)	(3.0)

*1 Figures before FY2019 and breakdown figures of segment are approximation for reference purpose only.

*2 Discontinued operations not included.

Special Items [Quarterly Data]

(Billions of Yen)

	FY2019				FY2020			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Total Special Items	(0.2)	0.0	(20.2)	(30.1)	8.7	(91.4)	(30.2)	(14.3)
Impairment loss	(0.7)	(0.7)	(18.0)	(24.5)	(0.0)	(87.0)	(20.2)	(11.1)
Loss on liquidation of subsidiaries and affiliates	-	-	-	-	-	-	-	(7.4)
Loss on sale and disposal of fixed assets	(0.6)	(0.5)	(2.3)	(6.5)	(0.2)	(3.0)	(1.2)	(1.8)
Special retirement expenses	(0.0)	(1.0)	(0.1)	(0.9)	(0.0)	(0.0)	(5.4)	(0.1)
Provision for loss on plant closure	-	-	-	-	-	-	(3.3)	-
Cancellation penalty	-	-	-	(0.0)	-	(0.5)	(1.4)	-
Gain on sale of property, plant and equipment	0.9	1.0	2.5	3.5	8.1	0.5	0.0	0.0
Gain on arbitration award	-	-	-	-	-	-	-	4.1
Share of profit of associates and joint ventures	-	-	-	-	-	-	2.7	0.1
Gain on business transfer	-	-	-	-	-	-	-	1.4
Gain on step acquisitions	-	-	-	-	-	-	1.3	-
Gain on sales of shares of subsidiaries and associates	0.4	0.1	-	-	0.9	-	-	0.3
Others	(0.2)	1.1	(2.3)	(1.7)	(0.1)	(1.4)	(2.7)	0.2

[Special Items by Business Segment]


Performance Products	0.2	(0.4)	(1.5)	(0.2)	0.8	(4.4)	(0.4)	(11.3)
Chemicals	0.0	(1.1)	(0.2)	(1.1)	(0.0)	(2.3)	(23.7)	(1.0)
Industrial Gases	(0.6)	1.0	1.7	0.0	-	(0.1)	2.8	(1.0)
Health Care	(0.0)	0.8	(17.1)	(25.2)	8.1	(84.6)	(3.0)	(0.1)
Others	0.2	(0.3)	(3.1)	(3.6)	(0.2)	(0.0)	(5.9)	(0.9)

Capital Expenditure, Depreciation & Amortization, R&D Expenses, and Number of Employees by Business segment


(Billions of Yen)

	Capital Expenditure		Depreciation & Amortization		R&D Expenses		Number of Employees
	FY2021 Actual	FY2020 Actual	FY2021 Actual	FY2020 Actual	FY2021 Actual	FY2020 Actual	FY2020 Actual
Performance Products	89.8	77.9	64.0	60.3	23.2	25.4	25,613
Chemicals	73.3	57.6	64.1	64.8	9.6	9.8	8,207
Industrial Gases	69.6	74.8	88.7	86.2	3.4	3.4	19,358
Health Care	20.9	22.6	16.4	16.9	76.5	82.9	7,236
Others	10.1	7.5	10.6	10.4	13.4	11.9	9,193
Total	263.7	240.4	243.8	238.6	126.1	133.4	69,607


Trend of Performance



Trend of Financial Position



(Billions of Yen)



References 2



**FY2020 Business Results
(April 2020 – March 2021)**

May 12, 2021

FY2020 Financial Results

	FY2020	Comparison to previous year			Comparison to forecasts	
		FY2019	Increase (decrease)	Change	Announced on Feb.3	Achieved
	Billion yen	Billion yen	Billion yen	%	Billion yen	%
Revenue	377.8	379.8	(2.1)	(0.5)	373.0	101.3
(Domestic)	313.0	314.0	(1.0)	(0.3)	312.2	100.3
(Overseas)	64.8	65.8	(1.1)	(1.6)	60.8	106.5
Overseas sales ratio	17.1%	17.3%			16.3%	
Cost of sales	190.4	181.0	9.3	5.2	187.5	101.5
Sales cost ratio	50.4%	47.7%			50.3%	
Gross profit	187.4	198.8	(11.4)	(5.7)	185.5	101.0
SG&A expense, etc.	166.4	179.7	(13.4)	(7.4)	168.5	98.7
(R&D expense)	72.6	79.4	(6.9)	(8.7)	72.5	100.1
Core operating profit	21.0	19.1	2.0	10.4	17.0	123.7
Non-recurring items*	(79.6)	(25.1)	(54.4)	-	(79.5)	-
Operating profit*	(58.5)	(6.1)	(52.4)	-	(62.5)	-
Financial income and loss*	0.8	(0.4)	1.2	-	-	-
Net profit attributable to owners of the Company*	(46.9)	0.1	(47.0)	-	(52.5)	-
Average exchange rate US\$	¥105.94	¥108.95			¥108.00	

*: Brackets indicate expense and loss


FY2020 Details of Revenue

	FY2020	Comparison to previous year			Comparison to forecasts	
		FY2019	Increase (decrease)	Change	Announced on Feb.3	Achieved
	Billion yen	Billion yen	Billion yen	%	Billion yen	%
Domestic ethical drugs	304.7	304.4	0.3	0.1	302.3	100.8
Priority products	183.0	177.1	5.9	3.3	183.0	100.0
Vaccines	42.6	39.0	3.6	9.3	41.6	102.5
Long-listed drugs, etc.	79.0	88.3	(9.3)	(10.5)	77.7	101.7
Overseas ethical drugs	50.2	49.7	0.5	1.0	47.0	106.8
Radicava	22.0	23.1	(1.2)	(5.1)	20.1	109.2
Royalty revenue, etc.	15.9	17.4	(1.5)	(8.9)	15.2	104.5

Revenue of Priority Products and Vaccines

	FY2020	Comparison to previous year			Comparison to forecasts	
		FY2019	Increase (decrease)	Change	Announced on Feb.3	Achieved
	Billion yen	Billion yen	Billion yen	%	Billion yen	%
Remicade	45.4	53.4	(8.0)	(15.0)	45.0	100.8
Simponi	42.3	41.0	1.4	3.4	42.7	99.2
Stelara	32.2	26.0	6.2	23.8	31.9	101.0
Tenelia	15.1	15.2	(0.1)	(0.8)	14.9	101.3
Canaglu	10.3	8.8	1.5	16.6	9.8	105.3
Canalia	9.7	6.7	3.0	44.6	9.3	104.7
Vafseo (launched in Aug.)	0.3	-	0.3	-	0.5	68.8
Lexapro	15.3	15.0	0.4	2.5	14.8	103.6
Rupafin	8.2	6.8	1.4	20.7	10.0	81.7
Imusera	4.1	4.2	(0.1)	(3.3)	4.1	100.1
Total of priority products	183.0	177.1	5.9	3.3	183.0	100.0
Influenza vaccine	14.4	12.6	1.8	14.0	13.2	109.1
Tetrabik	10.9	9.5	1.5	15.4	11.1	98.6
Mearubik	6.1	6.0	0.2	2.9	6.4	95.8
JEBIK V	5.2	5.2	0.0	0.4	5.3	97.7
Varicella vaccine	5.0	4.9	0.0	0.5	4.8	103.2
Total of vaccines	42.6	39.0	3.6	9.3	41.6	102.5
Total of priority products and vaccines	225.6	216.1	9.6	4.4	224.6	100.5

Revenue Trends



* Including a decline of "GILENYA® Royalty" amounts which will not be recognized as sales revenue during arbitration proceedings

	FY2021 forecasts	FY2020 actual	Increase / Decrease	
	Billion yen	Billion yen	Billion yen	%
Revenue	407.5	377.8	29.7	7.9
SG&A expense, etc.	189.0	166.4	22.6	13.6
R&D expense	85.0	72.6	12.4	17.2
Core operating profit	26.0	21.0	5.0	23.6
Non-recurring items*	4.0	(79.6)	83.6	-
Operating profit*	30.0	(58.5)	88.5	-
Net profit attributable to owners of the Company*	17.5	(46.9)	64.4	-

*: Brackets indicate expense and loss

Details of Revenue Forecasts

	FY2021 forecasts	FY2020 actual	Increase / Decrease	
	Billion yen	Billion yen	Billion yen	%
Domestic ethical drugs	286.3	304.7	(18.3)	(6.0)
Priority products	145.3	137.7	7.6	5.5
Vaccines	37.0	42.6	(5.6)	(13.1)
Long-listed drugs, etc.	104.0	124.4	(20.4)	(16.4)
Remicade*1	36.5	45.4	(8.8)	(19.4)
Overseas ethical drugs*2	100.6	50.2	50.4	100.3
Radicava	19.2	22.0	(2.7)	(12.4)
Royalty revenue, etc.	12.3	15.9	(3.6)	(22.6)

*1: Classified from priority product to long-listed drugs, etc. in FY2021. Figures in FY2020 was adjusted along with this for comparison.

*2: Expected an increase by commercialization of COVID-19 vaccine(MT-2766)

FY2021 Business Forecasts

Revenue Forecasts of Priority Products and Vaccines

	FY2021 forecasts	FY2020 actual	Increase / Decrease	
	Billion yen	Billion yen	Billion yen	%
Simponi	41.2	42.3	(1.1)	(2.7)
Stelara	42.7	32.2	10.5	32.4
Tenelia	14.4	15.1	(0.7)	(4.6)
Canaglu	10.1	10.3	(0.2)	(2.1)
Canalia	9.3	9.7	(0.4)	(4.2)
Vafseo	1.3	0.3	1.0	278.5
Lexapro	14.1	15.3	(1.3)	(8.2)
Rupafin	8.9	8.2	0.7	9.0
Imusera	3.3	4.1	(0.8)	(19.7)
Total of priority products	145.3	137.7	7.6	5.5
Influenza vaccine	14.3	14.4	(0.1)	(0.8)
Tetrabik	10.8	10.9	(0.2)	(1.5)
Mearubik	5.7	6.1	(0.5)	(7.5)
JEBIK V	1.3	5.2	(3.9)	(75.8)
Varicella vaccine	4.1	5.0	(0.8)	(16.8)
Total of vaccines	37.0	42.6	(5.6)	(13.1)
Total of priority products and vaccines	182.3	180.3	2.0	1.1



田辺三菱製薬

Status of research and development etc.

Major Global Development Pipeline

Progress and Targets for FY2021

Code	Indications	Stage	Progress /Targets for FY2021
MT-1186	ALS/oral suspension	P3	<ul style="list-style-type: none"> Global P3 study (long-term safety study) is ongoing. After obtaining the results of P3 study, NDA is to be filed in the U.S. in 3Q of FY2021.
ND0612	Parkinson's disease	P3	<ul style="list-style-type: none"> Global P3 study is ongoing.
MT-2766	Prophylaxis of COVID-19 (Plant-based VLP* vaccine)	P3	<ul style="list-style-type: none"> P3 study started in March is ongoing. Completion of NDA Submission in Canada in 2Q of FY2021, aiming at commercialization in 2021.
MT-7117	Erythropoietic protoporphyria (EPP) X-linked protoporphyria (XLP)	P3	<ul style="list-style-type: none"> Global P3 study is ongoing. The results of P3 study will be available in 4Q of FY2021.
	Systemic sclerosis	P2	<ul style="list-style-type: none"> The start of global P2 study was announced in March.
MT-3921	Spinal cord injury	P1	<ul style="list-style-type: none"> Global P2 study is planned to be started in 1Q of FY2021.

*VLP : Virus-Like Particle

■ Other Topics

- Mineralys Therapeutics, a licensee of **MT-4129**, announced in April that it will start P2 study for the treatment of hypertension.
- In May, the Company decided to discontinue development of **MT-5745 (STNM01)** acquired through the acquisition of Stelic Institute. we recorded an impairment loss of 3.9 billion yen for intangible assets.

Major Development Pipeline in Japan

Progress and Targets for FY2021

Code	Indications	Stage	Progress/Targets for FY2021
MT-0551	Neuromyelitis Optica Spectrum Disorder (NMOSD) * ¹	Approved	<ul style="list-style-type: none"> It was approved in May in Japan. Preparing for the launch after NHI price listing.
MT-5199	Tardive dyskinesia * ²	Filed	<ul style="list-style-type: none"> In April, the application for approval was submitted in Japan.
TA-7284	Diabetic nephropathy * ³	P3	<ul style="list-style-type: none"> The application for approval in Japan is scheduled to be submitted in 3Q of FY2021.

*1: Submitted in Korea and Taiwan

*2: Submitted in 5 Asian countries (Singapore, Thailand, Indonesia, Malaysia and Korea)

*3: Approved in Taiwan

■ Other Topics

- **MP-513 (domestic product name: TENELIA) OD Tablets** was approved in Japan in February. Preparing for the launch after NHI price listing.
- In March, the Company entered into an out-licensing agreement with DT-Axis for the clinical development and marketing of **a cognitive-behavioral therapy application, MTD-810.**

MT-2766

Medicago VLP Vaccine aims to prevent COVID-19



Phase 3 study started in March. Aim to commercialize in Canada in 2021

Category	Plant-based VLP (virus-like particle) vaccine
Origin	Medicago Inc. (Canada)
Development stage	Phase 3 (started rolling submission /Canada) ※MT-2766 was granted Fast Track designation by the U.S. FDA in February 2021
Indication	Prophylaxis of COVID-19
Phase 3 Summary	<ul style="list-style-type: none">• Subjects: The trial started in Canada and the U.S. and will soon start in other countries and enroll up to 30,000 subjects composed of healthy adults, elderly and adults with comorbidity.• Dosage and administration: Two doses of 3.75µg VLP vaccine candidate combined with GSK's adjuvant given 21 days apart.• Endpoints: Efficacy and safety. (comparison with placebo)
Future plans	Completion of NDA Submission in Canada in 2Q of FY 2021, aiming at commercialization in 2021

News release on March 17 and April 26, 2021

MT-7117

(generic name : dersimelagon)

Initiated Global Phase2 Clinical Trial in subject with Systemic Sclerosis

Mechanism of action	Selective melanocortin 1 receptor (MC1R) agonist
Development Stage	Phase 2
Indication	<ul style="list-style-type: none">Systemic sclerosis (SSc, scleroderma) is a rare, chronic, and systemic disease characterized by autoimmunity, vasculopathy, and fibrosis of the skin and internal organs.SSc includes limited cutaneous SSc which is less severe, and diffuse cutaneous SSc, which is characterized by skin thickening (fibrosis) and is associated with severe organ damage. <p>[Number of patients] prevalence in the US: approximately 300 patients per million</p>
Phase 2 study outline	<ul style="list-style-type: none">Evaluate efficacy, safety and tolerability of MT-7117 in subjects with diffuse cutaneous systemic sclerosis (male or female aged 18 to 75 years)Primary outcome measurement: The ACR CRISS composite score at Week 52. Estimated enrollment: 72 patients
Future plans	Top line data of Phase 2 study will be available in Q4 of FY2022

- A global Phase 3 trial of MT-7117 in patients with **erythropoietic protoporphyria (EPP)** or **X-Linked Protoporphyria (XLP)** is underway.

News release on March 31, 2021

MT-0551

(generic name : inebilizumab, Japan brand name : UPLIZNA)



Obtained a Japan regulatory approval for Neuromyelitis Optica Spectrum Disorder (NMOSD) in March

Mechanism of action	Humanized anti-CD19 monoclonal antibody
Origin	Horizon Therapeutics plc* (Ireland)
Indication	Prevention of relapses of NMOSD (including neuromyelitis optica) <ul style="list-style-type: none">• An autoimmune disease of the central nervous system characterized by severe optic neuritis and transverse myelitis and designated intractable disease.• Relapse may occur repeatedly, and a single relapse may lead to vision loss or wheelchair activity. 【Number of patients】 Approximately 4,000 patients in Japan
Features	<ul style="list-style-type: none">• A new mechanism of a broad depletion of B cells including antibody-producing plasmablasts and plasma cells• Convenience of a dosing interval of once every six months• Designated as an orphan drug in Japan in February 2020
Future plans	Preparing for the launch after NHI price listing

*Acquired Viela Bio, Inc. on March 2021.

- For **myasthenia gravis** and **IgG4-related disease**, global phase 3 clinical trials are being conducted in collaboration with Horizon Therapeutics.

News release on March 23, 2021

MT-5199 (generic name : valbenazine)

Filed a marketing authorization application for the treatment of Tardive Dyskinesia in Japan in April 2021

Mechanism of action	Vesicular monoamine transporter 2 (VMAT2) inhibitor
Origin	Neurocrine Biosciences, Inc. (USA)
Indication	<p>Tardive dyskinesia</p> <ul style="list-style-type: none">• Involuntary movement arising from the long-term administration of antipsychotic drugs or other drugs.• Symptoms, which differ by patient, are principally facial, but also in the extremities and torso. Severe cases can lead to dysphagia or respiratory distress.
Features	<ul style="list-style-type: none">• The first product for the treatment of tardive dyskinesia in Japan*• Orally administered once daily
Future plans	Launch in FY 2022 (planned)

*In the U.S., valbenazine was approved in 2017.

INGREZZA (valbenazine) is commercialized in the U.S. by Neurocrine Biosciences, Inc.

News release on April 22, 2021

"TENELIA OD Tablets" Approved

"New options" in the treatment of type 2 diabetes mellitus



「TENELIA OD Tablets」

- **The first OD (Orally Disintegrating*) tablets in DPP-4 inhibitors**
- Approved on Feb.5, 2021, will be launched soon after NHI price listing. Co-promotion with Daiichi Sankyo
- Domestic oral diabetes drug market : about ¥476.4bn (Source : IQVIA 2021 Feb MAT, NHI pricing base)
- Number with strongly suspected diabetes : about 10 mil
(Source : MHLW, The National Health and Nutrition Survey in Japan, 2016: <https://www.mhlw.go.jp/content/000681180.pdf>)
- Approximately 78% of diabetic patients are aged 65 years or older.
(Source : MHLW, The National Health and Nutrition Survey in Japan, 2019: <https://www.mhlw.go.jp/content/000710991.pdf>)
- Providing "New options" in the treatment of type 2 diabetes mellitus that are expected to further improve convenience and medication compliance for elderly patients and patients with impaired swallowing function

*When placed on the tongue, orally disintegrating tablets disintegrate in several 10 seconds due to saliva or a small amount of water. This is useful not only for the general public but also for the elderly, who cannot swallow tablets well, and for those who are restricted in fluid intake

(Source: PMDA: <https://www.pmda.go.jp/safety/consultation-for-patients/on-drugs/qa/0002.html>).

Major Development Pipeline List

As of April 25, 2021

Progress Update



Mitsubishi Tanabe Pharma

Research areas	Code	Region	Indications	P1	P2	P3	Filed	Approved
Central nervous system	MT-1186	Global	ALS/oral suspension					
	ND0612	Global	Parkinson's disease					
	MT-3921	Global	Spinal cord injury					
	MT-0551	Japan	Neuromyelitis Optica Spectrum Disorder (NMOSD)					
		Japan*	Myasthenia gravis					
	MT-5199	Japan	Tardive dyskinesia					
Immuno-inflammation	MT-7117	Global	Erythropoietic protoporphyria(EPP) X-linked protoporphyria(XLP)					
		Global	Systemic sclerosis					
	MT-2990	Global	Endometriosis					
	MT-5547	Japan	Osteoarthritis					
	MT-0551	Japan*	IgG4-related disease					
Vaccines	MT-2766	Global	Prophylaxis of COVID-19					
	MT-2654	Global	Prophylaxis of seasonal influenza/elderly					
	MT-2355	Japan	5 combined vaccine**					
Others	TA-7284	Japan	Diabetic nephropathy					


* Co-development with Horizon Therapeutics (Global study ongoing)

** Prophylaxis of pertussis, diphtheria, tetanus, poliomyelitis and prophylaxis of Hib infection in infants

Projects under Alliance Activities

Research areas	Code	Stage	Indications
Central nervous system	MT-8554	P2	Vasomotor symptoms associated with menopause
Others	MT-3995	P2	Non-alcoholic steatohepatitis (NASH)

Launch Plan for Major Development Pipeline



Cautionary Statement

The statements contained in this presentation is based on a number of assumptions and belief in light of the information currently available to management of the company and is subject to significant risks and uncertainties.

It contains information about pharmaceuticals including products under development, but is not intended for advertising or medical advice.

The forward-looking statements are based largely on company expectations and information available as of the date hereof, and are subject to risks and uncertainties, which may be beyond company control.

Actual results could differ materially due to numerous factors, including without limitation, marketing conditions and the effects of industry competition.